Imunon, Inc. Common Stock 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Imunon reported strong second quarter 2026 results, highlighting continued validation of their lead asset Imunon 001 and their therapeutic platform across clinical programs.
- The phase two Ovation 2 study showed a 14.7 month improvement in median overall survival in newly diagnosed patients, with a favorable safety profile and no serious immune-related adverse events.
- Preliminary data from the phase two minimal residual disease (MRD) trial showed lower MRD positivity rates (44% vs. 67%), higher circulating tumor DNA clearance (87.5% vs. 62%), and higher rates of no evidence of disease (100% vs. 56%) in the Imunon 001 arm compared to control.
- The pivotal phase three Ovation 3 study is enrolling ahead of plan, with approximately 0.5 patients per site per month versus the planned 0.3, and no new safety concerns identified by the independent data monitoring committee.
- Financially, R&D expenses increased to $1.5 million due to Ovation 3 costs, while general and administrative expenses decreased 20% to $1.3 million due to cost containment efforts.
- Net cash used in operations was $3.0 million for the quarter, with cash and equivalents of $6.9 million as of June 30, 2026, supported by a $10 million financing completed in June designed to minimize shareholder dilution.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Good morning. I will be your conference operator for today. At this time, I would like to welcome everyone to the Imunon second quarter 2026 financial results and business update conference call. I will now turn the call over to Valter Pinto, Managing Director of Investor Relations at KCSA Strategic Communications, for introductions.
Please go ahead. Thank you, operator, and good morning.
Welcome to the Imunon second quarter 2026 financial results and business update conference call. Joining us today are Stacy Lindborg, President and Chief Executive Officer, Dr. Douglas Faller, Chief Medical Officer, and Josh Blacher, Chief Financial Officer. Michael Tardugno, the company's Executive Chairman, is also on the line for the Q&A portion of today's call. Before we begin, I'd like to remind everyone that our remarks today include forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include, but are not limited to, statements regarding the timing and enrollment of the company's clinical trials, the potential of the company's therapies to address unmet medical needs, the market potential for its product candidates if approved, and the company's plans and expectations for its development programs.
Words such as may, will, expect, plan, anticipate, estimate, and intend identify these forward-looking statements, and actual results may differ materially from those projected. Additional information on the factors that could cause actual results to differ is detailed in Imunon's filings with the Securities and Exchange Commission, which are available at sec.gov and on the company's website. Forward-looking statements made on the call speak only as of today's date, and the company undertakes no obligation to update them except as required by law. With that, I'd now like to turn the call over to Dr. Stacy Lindborg.
Stacy, please go ahead. Thank you, Valter, and good morning, everyone.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring